WEDNESDAY, SEPTEMBER 28, 2016

BiondVax Pharmaceuticals, Cytovance Biologics prepare flu vaccine for Phase III trials

BiondVax Pharmaceuticals Ltd., a biopharmaceutical company focused on developing a universal flu vaccine, and Cytovance Biologics Inc., a contract development manufacturing company, have agreed to a Development and Manufacturing agreement for clinical batches of Biondvax’s M-001 universal flu vaccine for Phase III clinical trials.

"I am happy and proud of this new strategic relationship with Cytovance Biologics Inc., a U.S. leader in contract manufacturing with a significant track record in the production of clinical materials. This is a key development for BiondVax that will play a major role in accelerating the clinical development and large-scale manufacture of our universal flu vaccine, M-001. I believe that our vaccine will improve the lives of the millions of individuals who currently suffer and some of which die every year, from Influenza and its complications,” BiondVax Chief Operations OFficer Shimon Hassin said.

Phase III clinical batches will be manufactured by the end of 2016 in order for BiondVax to conduct studies in 2017-2018.
  
"Cytovance's state-of-the-art facilities and staff are prepared to deliver the highest quality of manufacturing services for BiondVax," Cytovance CEO and President Darren Head said.

Organizations in this story

BiondVax Science Park, 14 Einstein Street PO Box 4143 Ness Ziona, Israel 74140

Get notified the next time we write about BiondVax!